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GlutamateHuman reticulon 4 (RTN-4) has been identiﬁed as the neurite outgrowth inhibitor (Nogo). This protein contains a span
of 66 amino acids (Nogo-66)ﬂanked by twomembrane helices at the C-terminus.Wepreviously determined theNMR
structure of Nogo-66 in a native-like environment and deﬁned the regions of Nogo-66 expected to bemembrane em-
bedded. We hypothesize that aromatic groups and a negative charge hyperconserved among RTNs (Glu26) drive the
remarkably strong association of Nogo-66with a phosphocholine surface. Glu26 is an isolated chargewith no counter-
ion provided by nearby protein groups. Wemodeled the docking of dodecylphosphocholine (DPC) with Nogo-66 and
found that a lipid choline group could form a stable salt bridge with Glu26 and serve as a membrane anchor point. To
test the role of the Glu26 anion in binding choline, wemutated this residue to alanine and assessed the structural con-
sequences, the association with lipid and the afﬁnity for the Nogo receptor. In an aqueous environment, Nogo-66
Glu26Ala is more helical than WT and binds the Nogo receptor with higher afﬁnity. Thus, we can conclude that in
the absence of a neutralizing positive charge provided by lipid, the glutamate anion is destabilizing to the Nogo-66
fold. Although the Nogo-66 Glu26Ala free energy of transfer from water into lipid is similar to that of WT, NMR data
reveal a dramatic loss of tertiary structure for the mutant in DPC micelles. These data show that Glu26 has a key role
in deﬁning the structure of Nogo-66 on a phosphocholine surface. This article is part of a special issue entitled:
Interfacially Active Peptides and Proteins. Guest Editors: William C. Wimley and Kalina Hristova.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Reticulons (RTNs) aremembrane proteins found in the endoplasmic
reticulum (ER) of most eukaryotes. It has been proposed that RTNs
evolved when the endomembrane system developed ~1.7 billion years
ago [1]. RTNs function to establish curvature of the ER membrane [2]
and have been implicated in the assembly of the nuclear envelope [3],
ER-Golgi trafﬁcking and vesicle formation (reviewed in [4]). Some
viruses exploit the ability of host RTNs to drive lipid bilayers into1; CNS, central nervous system;
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00, USA. Tel.: +1 949 824 4487.membrane compartments, enabling the virus to sequester viral replica-
tion behind a host membrane (reviewed in [5]). In addition to deﬁning
the architecture and topology of a lipid membrane, RTNs have been
adapted for other cellular functions including: the regulation of apopto-
sis [6,7], inhibition of β-amyloid-converting enzyme 1 (BACE1) to block
amyloid formation [8,9], vascular remodeling [10], inhibition of angio-
genesis in the CNS [11], and inhibition ofmyelination [12]; and as an ax-
onal growth inhibitor, RTN-4 limits plasticity in the brain (reviewed in
[13,14]). RTNs have also been implicated in a range of neurodegenera-
tive diseases (reviewed in [15]). The C-terminal 150–200 amino acids
are common among all RTNs and are referred to as the reticulon homol-
ogy domain (RHD). RHDs have two hydrophobicmembrane-embedded
regions (Fig. 1B); between these helices is a span of 66 amino acids
(RHD-66) that extends beyond the membrane into the aqueous phase.
The N-terminal regions of RTNs can vary dramatically in length and
sequence, according to their distinct function.
RTN-4 is also known as the neurite outgrowth inhibitor (Nogo).
Nogo is expressed as three isoforms: Nogo-A, -B and -C splice variants
result in different N-terminal sequences; these can trafﬁc from the
ER to the plasma membrane. All Nogo variants share a common C-
terminal domain RHD, which includes the 66-residue extracellular
region (Nogo-66) [16–18]. Nogo-66 has been identiﬁed as one of several
Fig. 1. Structure and homology of Nogo-66. A) Ribbon diagram of Nogo-66 showing the lipid–protein interface of Nogo-66 (PDB ID: 2KO2); groups conserved among higher vertebrate
RHDs are highlighted (yellow: Y3, F19, F56; green: L61); a negative charge is hyperconserved (E or D) among all RHDs at position 26 (red: E26). B) surface representation of Nogo66 col-
ored according to electrostatic potential; facing the phosphocholine surface, E26 is visible at the base of a cavity (yellow circle) with no protein counter ion nearby. C) RTN domain orga-
nization; the N-terminus varies in length, sequence and function; M = membrane embedded. D) Sequence alignment of RHD-66 (extracellular region) of selected higher vertebrates;
conserved groups that contact lipid (featured in A and B) are highlighted.
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inhibitory activity by binding to the Nogo receptor (NgR) [19].
Recently, we determined the NMR structure of Nogo-66 embedded in
a native-like environment [20]. Nogo-66 is disordered in an aqueous en-
vironment, but folds into a ﬁve-helix bundle in dodecylphosphocholine
(DPC). We used accessibility to paramagnetic reagents and nuclear
Overhauser effects (NOEs) between protein and DPC to deﬁne the re-
gions of Nogo-66 that are either in contact with DPC or exposed to the
aqueous phase, this enabled us to orient the protein. In early functional
assays, the peptide corresponding to residues 31–55 of Nogo-66 was
found to have themost activity in blocking neuronal growth [17]. The res-
idues that are the most solvent exposed amino acids in our model of
Nogo-66 at the cell surface are also most active in binding NgR.
The function of Nogo as an axonal growth inhibitor has been well
established (reviewed in [13]), but the structural mechanisms by
which RTNs establish membrane curvature remains undeﬁned. Al-
though RTNs can have disparate functions, RHDs share a common func-
tion in the ER. Speciﬁc contacts between the RHD and lipid and the
dominant forces that enable the RHD to establish membrane curvature
are currently unknown. We evaluated amino acids that are conserved
among all RHDs and developed a list of groups that could be important
in lipid interactions. In Nogo-66, we found several positions conserved
in higher vertebrates that are in contact with lipid including aromatic
and hydrophobic side chains. The position, E/D26 in the 66-amino aciddomain was identiﬁed as hyperconserved in RTNs of all eukaryotes in
2003 [1]. Furthermore, the structure surrounding Glu-26 is interesting
because the side chain is positioned at the base of a cavity that could eas-
ily accommodate a phosphocholine (PC) with no positively charged pro-
tein groups in proximity to neutralize the Glu carboxylate. The distances
betweenGlu26 and the Lys or Arg side chains of helix 1 and 5make it im-
possible for direct interaction, but collectively or individually these
groups could form salt bridges to bind the choline and phosphate of a
PC molecule. We propose a model for the interaction of a single PC with
Nogo-66. Herewe explore the structural role of Glu26 andﬁnd that inter-
actions between Glu26 and the PC surface of a micelle or lipid vesicle in-
ﬂuence the Nogo-66 structure. Moreover, mutation of Glu26 to Ala has
structural consequences resulting in increased helical content in aqueous
solution, consistent with Glu26 destabilizing the fold when unpaired
with choline. Conversely, E26A shows signiﬁcantly decreased order and
helical content in a membrane-like environment revealing the role that
this Glu plays in deﬁning theNogo-66 structure at themembrane surface.
2. Materials and methods
2.1. Nogo-66 protein expression and puriﬁcation
A plasmid containing WT Nogo-66 has previously been described
[20]. The E26A mutant plasmid was prepared using quick-change
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were expressed with an N-terminal His6 tag and six additional amino
acids (MHHHHHHLVPRGM). The protein was expressed as described
previously. SDS-PAGE and MALDI mass spectrometry conﬁrmed puri-
ﬁed protein to be the correct molecular weight. Protein NMR samples
were prepared by dissolving lyophilized protein in 5 mM sodium ace-
tate to a ﬁnal concentration of 1 mM. DPC (Avanti Polar Lipids, Inc.)
was added to a ﬁnal concentration of 200 mM.
2.2. CD measurements
The secondary structure of Nogo-66was analyzed by CD spectrosco-
py in the far UV (185–250 nm) regions. Solutions of the proteinwere di-
alyzed against 5mM sodium acetate, pH 5.0.We choose pH 5 to balance
Nogo-66 solubility with maintaining the Glu side chain above the pKa.
We also collected data at pH 7 at a lower protein concentration and
found the same spectral features. 1.9 mg/ml WT and 1.3 mg/ml E26A
Nogo-66 samples were analyzed at 25 °C, in 1.0 nm wavelength inter-
vals using a JASCO Model 720 CD spectropolarimeter (JASCO, Easton,
MD) with a scan speed of 50 nm/min and average response time of
5 s. A total of 10 consecutive scans were accumulated for analysis. To
minimize light scattering inherent in lipid vesicles samples, data were
collected with a 0.1-mm path-length cell (NSG Precision Cells, Inc.,
Farmingdale, NY). DichroWeb, an online server providing various CD
analysis programs, was used to analyze the data [21]. The program
ContinLL was used to ﬁt the data and estimate the content of secondary
structure present using reference set SP175 [22].
2.3. Lipid partitioning assays
Todetermine the partition coefﬁcient for the transfer of Nogo-66WT
and E26A from water into lipid, CD wavelength spectra were collected
at varying lipid concentrations and the change in ellipticity at 222 nm
(θ, mdeg) was analyzed as described in [23]. 1,2-dimyristoyl-sn-glycero-
3-phosphocholine (DMPC) vesicles were extruded to 100 nm diameter
particles at 35 °C. Protein and lipid were diluted into separate tubes to
maintain a ﬁnal protein concentration of approximately 0.5 mg/ml,
5 mM sodium acetate, pH 5.0 with varying concentration of lipid
(0.01–10 mM). CD spectra were collected at 25 °C The fraction of pro-
tein partitioned into the lipid phase (fp) plotted as a function of lipid
concentration was ﬁt to the following equation to determine the parti-
tion coefﬁcient, KX.
fp ¼
KX L½ 
W½  þ KX L½ 
ð1Þ
where [W] is the concentration of water and [L] is the concentration of
lipid.
The free energy of transfer fromwater into lipid bilayerwas calculated
from the equation:
ΔG ¼−RT lnKX: ð2Þ
2.4. NMR measurements
NMR experiments were performed on a Varian Inova 800MHzNMR
spectrometer equipped with a 5 mm xyz, pulse-ﬁeld gradient triple
resonance probe. 15N-HSQC experimentswere performed each at a pro-
tein concentration of 1 mMWT (pH 4.0) and E26A (pH 4.5) Nogo-66 in
presence of 200 mM DPC at 35 °C, in 5 mM sodium acetate, 90% H2O/
10%D2O. Data were processed using NMRPipe [24].2.5. Cloning and expression of NgR
The protocol for production of the receptor, NgRwas adapted from a
previously described report [25] A pCRII-TOPO (Invitrogen) vector for
expression in mammalian cell culture, containing mouse Nogo receptor
was provided to us by Dr. Binhai Zheng (UCSD). The sequence of NgR
was veriﬁed and the Nogo ligand binding domain (residues 26–310)
was PCR ampliﬁed before subcloning into Pharmingen's pAcGp67A se-
cretion vector, which was designed to produce a His6 tag fused to the
C-terminus of NgR. The glycosylated, folded material was successfully
produced in Sf9 insect cells (Novagen), whichwere grown in BacVector
Insect cell Media (Novagen) as suspension cultures in a spinner ﬂask at
28 °C. The culture was infected with recombinant baculovirus at a cell
density of 1 × 106 cells/ml. The MOI (multiplicity of infection) deter-
mined for optimal expression was 5 pfu/ml, and the optimal period of
infection was 96 h. Cells were sedimented and the media supernatant
with secreted NgR was concentrated 10-fold. Nickel resin was added
to the concentrated media, and the standard protocol described by
Qiagen for puriﬁcation of His6 tag proteins under native conditions
was used. The receptor was dialyzed into HBS buffer (HEPES buffered
saline pH 7.2, 5 mM Hepes), and concentrated to 2–3 mg/ml.
2.6. Receptor binding assay
The phage-Nogo-66 vector has been described previously [26]. The
mutation E26A was made using QuikChange mutagenesis, and the
mutation conﬁrmed by DNA sequencing. Phage production and isola-
tion has been described [26]. A phage-based ELISA was used to assess
display levels of WT Nogo-66 on the surface of the M13-KO7+ phage
by immobilizing an anti-FLAG antibody on the ELISA plate. Followed
phage-based ELISA protocol as described in [26]. A single microtiter
plate was used to assay simultaneously the display levels (A0) as well
as binding (A) of Nogo-66 wild-type and variant to immobilized NgR.
The ratio (A/A0) represents the apparent binding afﬁnity, KA:
KA ¼
A
A0
ð3Þ
where
A0 = The absorbances measured in wells coated with AntiFlag anti-
body. This value quantiﬁes display levels of Nogo-66 wild-type and
variant on the phage surface.
A= The absorbancesmeasured in wells coated with NgR. This value
quantiﬁes binding levels of Nogo-66 wild-type and variant to NgR
[27].
3. Results
Previously, we found that Nogo-66 was disordered in solution but
folded into a structure thatwas 85% helical in the presence of DMPC ves-
icles [20]. Thus, the structure of Nogo-66 is driven by lipid interactions.
To develop a list of potential protein/lipid interactions that could con-
tribute in deﬁning the protein fold, we mapped conserved positions
onto the Nogo-66 structure. RTN sequences include one position
that is hyperconserved among all RHDs (Fig. 1D red highlight) and
other groups that are conserved within the RTNs of higher vertebrates
(e.g., Fig. 1D yellow, green highlight) [1]. The positions of proposed
lipid-interacting groups conserved in higher vertebrates (Tyr3, Phe19,
Phe56, Leu61) and the hyperconserved Glu26 are depicted in the struc-
ture of Nogo-66 in Fig. 1A. There are other groups conserved in higher
vertebrates that appear to participate in intra-molecular helix–helix
interactions (Arg1–Asp/Glu32, Leu65) or modulate secondary structure
(Gly16, Pro18). These may play a role in folding the RHD-66 but do not
appear to interact directly with lipid based on our previous study of
accessibility and NOE contacts to DPC.
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served Glu26 side chain is positioned at the base of a cavity and it is not
involved in any interactions with charged functional groups from the
protein that could neutralize the carboxylate. A model of PC binding in
the Glu26 cavity shows that the choline group ﬁts very well (Fig. 2A).
In fact, NOEs were previously found between protein groups and the
DPC headgroup (Fig. 2B). Other examples of PC-protein binding are
shown in Fig. 2C–E. Since it appears plausible that the Glu26 cavity in
Nogo-66 could similarly bind PC, we hypothesized that Glu26 could
play a role in the determining the protein structure; we tested this by
mutation of Glu26 to Ala, a group unable to bind choline through ionic
interactions.
3.1. Secondary structure and partitioning of E26A into the lipid phase
The structural features of Nogo-66 wild type (WT) have been de-
scribed by circular dichroism (CD) and NMR spectroscopies [20].
These experiments were performed in the aqueous phase where func-
tional assays have shown Nogo-66 is active as an axonal growth inhib-
itor, and in the presence of lipid or detergent. We mutated Glu26 to
alanine and compared CD spectra of this sample to Nogo-66 WT in
both the aqueous phase and in the presence of DMPC lipid vesicles.
We assessed the secondary structure of E26A using CD in Fig. 3A. The
CD spectrum of Nogo-66 WT in water features little helical content
(15%) and a substantial contribution of random coil below 205 nm. In
contrast, the CD spectrum of themutant E26A shows a canonical helical
signature, estimated to be 38% helix (Fig. 3A blue). Previously, weFig. 2. A) Model of a single DPC molecule docked into the Nogo-66 Glu26 cavity by manually a
previously determined between protein and DPC guide placement of the DPC phosphocholine
known to bind the choline cation of a phosphocholine group via interaction with either a Glu
ID: 1B09) binds a PC at the protein surface through ionic interactions forming a salt bridge b
binds the choline using aromatic ring π–cation interactions. E) The enzyme PfPMT (PDB ID: 3U
and ionic interactions.demonstrated that addition of lipid vesicles to Nogo-66 WT induces a
dramatic increase in helical content (to 85% helix) [20]. We performed
a similar measurement for E26A but found a more modest increase in
helical content when lipid was added, E26A is estimated to be 64% heli-
cal in DMPC. Based on these CDdata, E26A is ~23%more helical inwater
but ~21% less structured in the presence of lipid compared toWT; trans-
fer of E26A into the lipid phase only increases the helical content by
~16%.
Since the lipid bilayer is a liquid phase, the partition coefﬁcient, KX
is the correct term to compare the afﬁnities of Nogo-66 WT and E26A
with the lipid phase [23]. This can be calculated from a change in ellip-
ticity (θ, mdeg) if a peptide or protein shows substantial folding in the
presence of lipid. We measured CD spectra of WT and E26A with
increasing DMPC lipid concentration and normalized the change in el-
lipticity at 222 nm between the two samples to determine the fraction
of protein (fp) partitioned into lipid. Fig. 3B shows the partitioning of
E26A compared to WT. Notably, the two proteins transfer favorably
into the lipid phase with very similar partition coefﬁcients (WT: KX =
1.8 × 105; E26A: KX = 1.2 × 105). The corresponding free energies
of transfer are virtually identical: ΔG = −5.8 kcal/mol for WT and
ΔG =−5.6 kcal/mol for E26A.
3.2. NMR characterization of E26A
We prepared a 15N-labeled sample of Nogo-66 E26A and collected
15N-HSQC NMR spectra as a measure of tertiary structure. Although
CD data described above indicate that E26A is more helical in andjusting the position of DPC and cationic side chains. Helices 1–5 are numbered. B) NOEs
in contact with helices 1 and 5 and in proximity to Glu26 [20]. Several other proteins are
or Asp carboxylate and/or aromatic π–cation bonding. C) Human C-reactive protein (PDB
etween choline and Glu81. D) The antibody MC/Pc603 Fab–PC complex (PDB ID: 2MCP)
JC) produces PC as a product. In this case, the protein binds choline using both π–cation
Fig. 3. Secondary structure and lipid partitioning of WT and E26A Nogo-66 deter-
mined by CD spectroscopy. A) Comparison of CD spectra of WT (red) and E26A (blue) in
an aqueous environment (5 mM Na acetate, pH 5.0, 25 °C). An increase in helical content
(signal at 222 nm) is visible in themutant spectra, WT is approximately 15% helical; E26A
is calculated to be 38%. Addition of DMPC lipid vesicles (100 nmdiameter) to E26A result-
ed in a signiﬁcant increase in helical secondary structure (64%), but less than the increase
seen forWT (85%) [20]. B) A plot of the fraction of protein in the lipid phase (calculated as
1− normalized θ222 nm) with increasing lipid concentrations. The partition coefﬁcient for
E26A (KX = 1.2 × 105) is only slightly lower than that of WT (KX = 1.8 × 105).
2354 A. Alhoshani et al. / Biochimica et Biophysica Acta 1838 (2014) 2350–2356aqueous environment compared to WT, we found no long range NOEs
in NMR experiments performed on E26A in water (this is similar to
the results of NMR experiments on WT in an aqueous environment
[20]). In addition, the protein amide groups of E26A exchange immedi-
ately with D2O, indicating a lack of stable structure. Previously, WT
Nogo-66was found to be highly ordered in DPC, giving one set of strong
NMR signals with many long-range NOEs [20]. In contrast, the 15N-
HSQC spectra of E26A in DPC is disordered with broad signals in
the random coil region (Fig. 4). The protein in DPC appears to bemolten
and we ﬁnd only a few NOEs in the E26A NOESY spectrum. Although
Nogo-66 WT samples remained soluble for weeks at low pH, the
E26A mutant is prone to aggregation under the same conditions.
Comparison of NMR spectra for WT and E26A show a dramatic change
in structure; the mutant spectra reveal conformational heterogeneity
for this species.3.3. Nogo receptor binding
Functional assays have largely been performed on Nogo-66 in the
aqueous phase. Although Nogo-66 is disordered in water, it is active in
blocking neuronal outgrowth. It is possible that Nogo-66 folds into a he-
lical bundle on the receptor surface with a conformation similar to that
of the lipid-bound state. Since E26Awas found to stabilize a helical con-
formation for Nogo-66 (Fig. 3A), we chose to assess receptor binding for
this mutant under conditions similar to functional assays (aqueous
phase). The use of phage display has proven a sensitive indicator of
Nogo-66 binding to the receptor [16]. Nogo-66 and the NgR are not
soluble at the same pH; this presents a challenge for binding assays.
We have determined that the NgR is unfolded at the pH optimal for
Nogo-66 solubility (pH 4) and Nogo-66 begins to precipitate above pH
5 where the receptor is stable. Phage display is a powerful technique
in determining binding of a large library of mutant proteins in a single
measurement. Display of the protein Nogo-66 on a phage particle offers
another signiﬁcant advantage: the phage particle is an enormous solu-
bility tag. Phage can be concentrated to a point where they form liquid
crystals and still remain soluble. Expression of Nogo-66 on the phage
surface keeps Nogo-66 in solution and monodisperse, allowing for
robust binding assays.
Monotopic membrane proteins, like Nogo-66, can be displayed con-
sistently using a mutant helper phage, termed M13-KO7+ or KO7+, to
package the phage. KO7+ incorporates an extra positively-charged
functionality into the phage coat, which can better mimic the zwitter-
ionic composition of phospholipid head groups [26]. In the experiments
reported here, Nogo-66 is displayed as a fusion to the major coat pro-
tein, P8 on the surface of KO7+ packaged phage particles. A FLAG epi-
tope fused to the N-terminus allows estimation of relative levels of the
displayed proteins.
After successful mutagenesis of the Nogo-66WT phagemid to incor-
porate the E26A point mutation, a phage-based ELISA conﬁrmed the
display of the Nogo-66 E26A variant. In this assay, an anti-FLAG anti-
body was immobilized on a 96-well microtiter plate. Subsequent to
the wells being blocked with BSA, Nogo-66 E26A-displayed phage was
incubated with the anti-FLAG antibody. The wells were washed to re-
move any unbound phage. Anti-M13 antibody speciﬁc to the phage
was then incubated, and the relative levels of displayed Nogo-66 WT
and E26A variant were measured by HRP activity (supplemental infor-
mation, Fig. S1). Following conﬁrmation of the successful display of
the Nogo-66 variant, the binding of the phage-displayed Nogo-66
E26A to NgR was examined (Fig. S1). In order to determine the relative
binding afﬁnity of the Nogo-66 variant from the absorbance levels, the
display levels and binding levels were measured on the same ELISA
plate (Figs. 5 and S1). Negative controls included binding to NgR
by KO7+ phage without Nogo-66 displayed and binding of phage-
displayed Nogo-66, wild-type and variant to the blocking agent, BSA;
as expected, the negative controls for the Nogo-66 variants displayed
essentially no binding (Fig. S1).
As shown previously [27], the ratio of the Nogo-66 binding levels (A)
to display levels (A0) has a linear correlation to the KA for the interac-
tion, provided the concentration of the target protein (NgR) greatly ex-
ceeds the concentration of the displayed protein. This is a reasonable
assumption for a phage-displayed 7.5 kD protein. Thus, a correlation
likely exists between the apparent and actual KA of the NgR binding to
Nogo66 wild-type and the variant. The binding afﬁnity as apparent KA
of the Nogo-66 E26A relative to wild-type is represented in Fig. 5. The
mutation of Glu26 to Ala resulted in a four-fold increase in afﬁnity to
the receptor.
4. Discussion
Many proteins that act at the membrane interface would be expect-
ed to recognize and bind PC. Interactions between positively charged
Arg and Lys side chains and the phosphate or other lipid anion have
Fig. 4. Tertiary structure of WT and E26A Nogo-66 in DPC assessed by NMR spectroscopy. 800 MHz 15N HSQC spectra of A) WT and B) E26A Nogo-66 in 200 mM DPC.
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er, choline binding has been less characterized. Protein crystal struc-
tures with good density describing the position of the PC reveal two
major contributors to binding choline: aromatic π–cation interactions
andGlu or Asp carboxylate-choline ionic interactions. Theﬁrst structure
showing a bound PC was an antibody determined by the Davies labora-
tory (Fig. 2D, [28]). In that structure, three aromatic residues Trp107,
Tyr33, Tyr100 form a perfect pocket for the positively-charged choline
group, highlighting π–cation binding. Human C-reactive protein (CRP)
levels are elevated in response to acute infection, and it binds to PC on
the surface of dead cells to initiate clearance. From the crystal structure
of CRP, it is clear that the positively charged choline moiety of PC is
in contact with the negatively charged Glu81 side chain, whereas
the phosphate group interacts with protein-bound calcium (Fig. 2C,
[29]). Another example of PC binding is seen in the structure of
phosphoethanolamine methyltransferase from Plasmodium falciparum
(PfPMT). In this case, a mixed π and anion pair: Tyr160 and Asp128,
interact with choline to stabilize the PC enzyme product (Fig. 2E, [30]).Fig. 5. Apparent binding afﬁnity of Nogo-66 WT and E26A mutant to the Nogo receptor.
The apparent binding afﬁnity is calculated as the apparent KA of the ligand–receptor inter-
action. The apparent KA is determined as the ratio of the binding levels of the protein
(Nogo-66 WT or E26A) with its target (NgR) (A) to the amount of displayed protein
(Nogo-66 WT or E26A) on the phage surface (A0) [27]. A single microtiter plate was
used to simultaneously measure display levels and binding levels of Nogo-66 WT and
E26A mutant. Each concentration was in triplicate and the average plotted. Standard
errors are shown. In the range where the apparent KA is linear, the mutant E26A shows
a binding afﬁnity for NgR that is four-fold higher than that of WT.Although we previously performed NMR experiments of Nogo-66 in
DPC, the NMR structure calculation relied only on NOE distance con-
straints between protein groups; no distance constraints to DPC mole-
cules were included and the structure calculation was performed on the
proteinmolecule alone (without lipid) [20]. Notably, the NOE constraints
limited to protein–protein contacts created a cavity near Glu26 that can
accommodate exactly one PC molecule in the Nogo-66 structure. Tyr22
is one helical turn from Glu26 and is positioned to π–cation bond with
choline inNogo-66providing additional stabilization in PCdocking; how-
ever, this Tyr is not conserved in all RHDs.
The results presented here show that structural inﬂuence of Glu26
depends on the environment of the protein — when either dissolved
in an aqueous solvent or partially embedded at a PC surface. A summary
of the structural features present under each condition is shown in
Fig. 6. Both WT and E26A Nogo-66 have similar partition coefﬁcients
(KX) of transfer fromwater into the lipid phase, but dramatically differ-
ent structures on a PC surface. WT folds into a single conformer in DPC
but E26A, unable to form a stable salt bridge to choline, is disorderedFig. 6. Summary of the effect of Glu26 mutation in Nogo-66. Although both proteins are
strongly associated with lipid, E26A is more disordered than WT. In contrast, E26A is
more helical in the aqueous phase than WT and binds the receptor with higher afﬁnity.
2356 A. Alhoshani et al. / Biochimica et Biophysica Acta 1838 (2014) 2350–2356and less helical. The similarity in transfer energy betweenWT and mu-
tant when partitioning into lipid could be accounted for by compensat-
ing effects; an energetically favorable increase in entropy of disordered
E26A in DPC could compensate for the destabilization resulting from a
lost salt bridge between Glu and the lipid headgroup.
In an aqueous environment, Nogo-66 WT is active in functional as-
says but maintains a very disordered structure. In contrast, mutation
of the buried Glu26 charge to Ala stabilizes helical conformations and
increases helical content by ~23% in E26A. Moreover, Nogo-66 E26A
has a much higher afﬁnity for the receptor thanWT in an aqueous envi-
ronment; this effect ismost likely a consequence of stabilized secondary
structure in the lipid-free state. Although a complete structure of the
complex between NgR, Nogo-66 and lipid has not been determined,
these studies provide insight into the state of Nogo-66 when binding
the receptor. We observe that the interaction of Glu26 with lipid stabi-
lizes theWT protein fold. In contrast, when lipid is absent Glu26 desta-
bilizes both the helical fold and receptor binding. The region 31–55 is
known to contain residues sufﬁcient for Nogo-66 function; Glu26 is po-
sitioned on the opposite protein face compared to the functional groups.
The ability of a position within the interior of a compact helical bundle
(Glu26) to affect receptor binding when it is not among the residues
expected to make up the binding interface suggests a model where
Nogo-66 folds on the receptor into a structure similar to that induced
by lipid.
The RHD-66 domain isﬂanked by twomembrane-embedded helices
that are believed to induce curvature of the ER membrane. These struc-
tures would be expected to stabilize the RHD-66 structure, both in
anchoring the protein to the membrane and in extending the N- and
C-terminal helices. It is also expected that the RHD-66 would be more
stable in a natural membrane than in DPCmicelles. Compared to planar
bilayers, micelles are highly curved andmuchmore dynamic. It is possi-
ble that the loss in structure seen in the lipid-associated state for the
E26Amutant is not as pronounced in the context of the full-length pro-
tein and natural cell membranes. Nevertheless, a system that is on the
cusp of stability is actually very useful in understanding protein folding.
Proteins that are extremely stable will often not show a measurable ef-
fect from a single mutation; this can make it difﬁcult to determine the
relative contributions of individual amino acids to the overall protein
stability. In deconstructing the RHD, we have found that Nogo-66 is an
excellent model for testing the forces that drive protein folding at a
lipid interface as well as providing speciﬁc detail on the RHD-66 fold.
The structure of Nogo-66 in DPC is entirely consistent with functional
assays and these studies show that Nogo-66 is an autonomous folding
unit that uses a negative charge at position 26 to anchor the protein to
the membrane surface. Nearby aromatic rings can also anchor Nogo-
66 in the membrane and contribute to the lipid-induced fold. In addi-
tion, there are several other Glu/Asp side chains conserved in higher
vertebrates that could interact with choline and drive docking into
the membrane leaﬂet. Studies are ongoing to extend the structure of
Nogo-66 with the ﬂanking membrane embedded regions and deﬁne a
complete RHD structure.Acknowledgements
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